Get started
Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

TARS chart


Full chart

TARS upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.84 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−3.81 USD
Net income (FY)
‪−135.89 M‬ USD
Revenue (FY)
‪17.45 M‬ USD
Shares float
‪32.58 M‬
Beta (1Y)
0.65

Employees


Employees (FY)
244
Change (1Y)
+157 +180.46%
Revenue / Employee (1Y)
‪71.50 K‬ USD
Net income / Employee (1Y)
‪−556.94 K‬ USD

About Tarsus Pharmaceuticals, Inc.


Sector
Health Technology
CEO
Bobak Azamian
Headquarters
Irvine
Website
tarsusrx.com
Founded
2017
FIGI
BBG00RB9BNQ7
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

TARS news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of TARS is 49.12 USD — it has increased by 2.54% in the past 24 hours. Watch Tarsus Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Tarsus Pharmaceuticals, Inc. stocks are traded under the ticker TARS.
TARS stock has risen by 6.09% compared to the previous week, the month change is a −10.11% fall, over the last year Tarsus Pharmaceuticals, Inc. has showed a 92.33% increase.
We've gathered analysts' opinions on Tarsus Pharmaceuticals, Inc. future price: according to them, TARS price has a max estimate of 84.00 USD and a min estimate of 41.00 USD. Watch TARS chart and read a more detailed Tarsus Pharmaceuticals, Inc. stock forecast: see what analysts think of Tarsus Pharmaceuticals, Inc. and suggest that you do with its stocks.
TARS reached its all-time high on Dec 18, 2020 with the price of 63.69 USD, and its all-time low was 10.80 USD and was reached on May 9, 2022. View more price dynamics on TARS chart.
See other stocks reaching their highest and lowest prices.
TARS stock is 5.18% volatile and has beta coefficient of 0.65. Track Tarsus Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Tarsus Pharmaceuticals, Inc. there?
Today Tarsus Pharmaceuticals, Inc. has the market capitalization of ‪1.88 B‬, it has decreased by −14.63% over the last week.
Yes, you can track Tarsus Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Tarsus Pharmaceuticals, Inc. is going to release the next earnings report on Mar 17, 2025. Keep track of upcoming events with our Earnings Calendar.
TARS earnings for the last quarter are −0.61 USD per share, whereas the estimation was −0.94 USD resulting in a 35.09% surprise. The estimated earnings for the next quarter are −0.74 USD per share. See more details about Tarsus Pharmaceuticals, Inc. earnings.
Tarsus Pharmaceuticals, Inc. revenue for the last quarter amounts to ‪48.12 M‬ USD, despite the estimated figure of ‪43.18 M‬ USD. In the next quarter, revenue is expected to reach ‪58.80 M‬ USD.
TARS net income for the last quarter is ‪−23.42 M‬ USD, while the quarter before that showed ‪−33.29 M‬ USD of net income which accounts for 29.65% change. Track more Tarsus Pharmaceuticals, Inc. financial stats to get the full picture.
No, TARS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jan 24, 2025, the company has 244.00 employees. See our rating of the largest employees — is Tarsus Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Tarsus Pharmaceuticals, Inc. EBITDA is ‪−139.44 M‬ USD, and current EBITDA margin is −815.50%. See more stats in Tarsus Pharmaceuticals, Inc. financial statements.
Like other stocks, TARS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Tarsus Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Tarsus Pharmaceuticals, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Tarsus Pharmaceuticals, Inc. stock shows the buy signal. See more of Tarsus Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.